What would you consider to be an appropriate amount to spend on R&D then? Especially considering their cash.The POC research on the ovarian test is completed, the commercial assay is already under development. They’ve got another study due in December AND they managed to do another two studies on BC and OC In high risk women last quarter.
The next round of research and development is contingent on the completion of the commercial assay. That’s the priority because that will be the product that brings them the revenue that shareholders actually want.
What would you consider to be an appropriate amount to spend on...
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
62.5¢ |
Change
0.050(8.70%) |
Mkt cap ! $65.94M | |||
| Open | High | Low | Value | Volume |
| 57.5¢ | 63.0¢ | 57.5¢ | $117.5K | 196.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 59.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 62.5¢ | 2484 | 2 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |